Pediatric multiple sclerosis: epidemiology, clinical aspects, diagnosis and treatment.

Abstract

Neurodegenerative Disease ManagementVol. 7, No. 6s SupplementPediatric multiple sclerosis: epidemiology, clinical aspects, diagnosis and treatmentAngelo GhezziAngelo Ghezzi*Author for correspondence: E-mail Address: angelo.ghezzi@asst-valleolona.it Centro Studi Sclerosi Multipla, Ospedale di Gallarate, Via Pastori 4, 21013, Gallarate, ItalySearch for more papers by this authorPublished Online:16 Nov 2017https://doi.org/10.2217/nmt-2017-0037AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: diagnosisMRIpediatric multiple sclerosisReferences1 Ghezzi A, Baroncini D, Zaffaroni M, Comi G. Pediatric versus adult MS: similar or different? Mult. Scler. Demyelinating Disord. 2, 5 (2017).Crossref, Google Scholar2 Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol. Sci. 25(Suppl. 4), S336–S339 (2004).Crossref, Medline, Google Scholar3 Renoux C, Vukusic S, Mikaeloff Y et al. Natural history of multiple sclerosis with childhood onset. N. Engl. J. Med. 356(25), 2603–2613 (2007).Crossref, Medline, CAS, Google Scholar4 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69(2), 292–302 (2011).Crossref, Medline, Google Scholar5 Krupp LB, Tardieu M, Amato MP et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult. Scler. 19(10), 1261–1267 (2013).Crossref, Medline, Google Scholar6 Verhey LH, Branson HM, Shroff MM et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol. 10(12), 1065–1073 (2011).Crossref, Medline, Google Scholar7 Neuteboom RF, Boon M, Catsman Berrevoets CE et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 71(13), 967–973 (2008).Crossref, Medline, CAS, Google Scholar8 Heussinger N, Kontopantelis E, Gburek-Augustat J et al. Oligoclonal bands predict multiple sclerosis in children with optic neuritis. Ann. Neurol. 77(6), 1076–1082 (2015).Crossref, Medline, Google Scholar9 Hacohen Y, Absoud M, Deiva K et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol. Neuroimmunol. Neuroinflamm. 2(2), e81 (2015).Crossref, Medline, Google Scholar10 Sadaka Y, Verhey LH, Shroff MM et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann. Neurol. 72(2), 211–223 (2012).Crossref, Medline, Google Scholar11 Ghezzi A. Randomized clinical trials (RCTs) in pediatric multiple sclerosis: are they really necessary? Mult. Scler. 23(7), 1042–1043 (2017).Crossref, Medline, Google Scholar12 Ghezzi A, Banwell B, Boyko A et al. The management of multiple sclerosis in children: a European view. Mult. Scler. 16(10), 1258–1267 (2010).Crossref, Medline, Google Scholar13 Chitnis T, Tenembaum S, Banwell B et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult. Scler. 18(1), 116–127 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByObesity in Pediatric-Onset Multiple Sclerosis20 July 2021 | Neurology - Neuroimmunology Neuroinflammation, Vol. 8, No. 5Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review25 May 2021 | Children, Vol. 8, No. 6 Vol. 7, No. 6s Follow us on social media for the latest updates Metrics Downloaded 201 times History Received 8 September 2017 Accepted 19 September 2017 Published online 16 November 2017 Published in print November 2017 Information© 2017 Future Medicine LtdKeywordsdiagnosisMRIpediatric multiple sclerosisFinancial & competing interests disclosureA Ghezzi has received honoraria from Almirall, Biogen, Genzyme, Merck-Serono, Novartis and Teva; and speakers’ bureau from Biogen, Genzyme, Merck-Serono, Novartis and Teva. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Writing assistance was provided by Content Ed Net (Madrid, Spain), with funding from Almirall SA (Barcelona, Spain).PDF download